LHO : View Resource : Collection : Commissioning - PCT Clinical Exceptions

Return to Listing

Commissioning - PCT Clinical Exceptions - OphthalmologyA collection of clinical exceptions reviews on eye disorders.

Home Location	LHO
National or Regional	Regional

start of decorative frame for

Relationships

start of content for

Has part

Adalimumab for uveitis
Bevacizumab for chroroidal neovascularisation secondary to idiopathic juxtafoveal retinal telangiectasia
Bevacizumab for macular oedema of possible adult-onset Coat’s disease
Intravitreal bevacizimab forchoroidal neovascularisation secondary to angioid streaks
Intravitreal bevacizumab for central retinal vein occlusion
Intravitreal bevacizumab for chronic central serous retinopathy
Ranibizumab for choroidal neovascularisation (CNV) due to choroidal rupture after blunt trauma
Avastin (Bevacizumab) for a patient with choroidal neovascularisation (CNV) secondary to degenerative myopia (mCNV
Avastin (Bevacizumab) for a patient with left eye inflammatory choroidal neovascularisation (CNV) secondary to punctate inner choroidopathy (PIC)
Bevacizumab for choroidal neovascularisation due to choroidal rupture
Intravitreal bevacizumab for inflammatory choroidal neovascularisation secondary to punctuate inner choroidopathy
Intravitreal ranibizumab for macular oedema following central retinal vein occlusion (CRVO)
Intravitreal ranibizumab for myopic choroidal neovascular membrane
Avastin® (bevacizumab) for choroidal neovascularisation associated with angioid streaks
Bevacizumab (Avastin) or Ranibizumab (Lucentis) for a 64 year old with chronic macular oedema secondary to central retinal vein obstruction
Infliximab for uveitis in juvenile idiopathic arthritis
Intravitreal ranibizumab or bevacizumab for choroidal neovascularisation secondary to myopia
Lucentis for punctate inner choroidopathy with choroidal neovascularisation
Lucentis for subfoveal choroidal neovascular membranes (SCNV)
Macugen therapy for a patient with exudative (wet) age related macular degeneration (ARMD)
Photodynamic therapy (PDT) for central serous chorio-retinopathy (CSCR)
Photodynamic therapy (PDT) with verteporfin (Visudyne®)
Photodynamic therapy (PDT) with verteporfin for a 35 year old patient with right choroidal haemangioma with neurosensory detachment of the right macula
Photodynamic therapy with verteporfin for chronic bilateral subfoveal central serous retinopathy
Ranibizumab for a 73 year old with wet age-related macular degeneration (AMD) in his only seeing eye
Ranibizumab for a patient with bilateral age-related macular degeneration (AMD) with retinal angiomatous proliferation (RAP)
Ranibizumab for choroidal neovascularisation (CNV) associated with angioid streaks
The use of antiVEGF in myopia choroidal neovascular membranes (CNVM)
Verteporfin for the treatment of a patient with chronic central serous retinopathy
Infliximab infusions to treat ocular sarcoidosis
Photodynamic therapy (PDT) for punctate inner choroidopathy (PIC) with choroidal neovascularisation (CNV)
Infliximab for the treatment of uveitis in a 10 year-old child

end of content for

end of decorative frame for

start of decorative frame for

You might also be interested in...
start of content for Commissioning - PCT Clinical Exceptions - Reviews Commissioning - PCT Clinical Exceptions - Background resources Commissioning - PCT Clinical Exceptions - Plastic surgery Commissioning - PCT Clinical Exceptions - Lymphatic diseases - Resources Commissioning - PCT Clinical Exceptions - Caesarian births More... end of content for

end of decorative frame for

start of decorative frame for Type and Language

Type and Language

start of content for Type and Language

Resource Type

collection

end of content for Type and Language

end of decorative frame for Type and Language